01/05
Headlines

Gold

Hot Watch List: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Enanta Pharmaceuticals (NASDAQ:ENTA), Cheesecake Factory Incorporated (NASDAQ:CAKE), Randgold Resources Limited (NASDAQ:GOLD), OvaScience, Inc. (NASDAQ:OVAS)

Ryan Holtz03 mins

On 7 AUG OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced second quarter 2014 financial results. Revenue for the three and six months ended June 30, 2014 was $4.9 million and $16.7 million, respectively.  This compares with $6.3 million and $11.4 million, respectively, in the same periods in 2013. Revenue earned in the second quarter of 2014 consists…

Read More

Hot Movers: Novartis AG (NYSE:NVS), IMAX Corporation (NYSE:IMAX), ImmunoGen (NASDAQ:IMGN), bluebird bio (NASDAQ:BLUE), Randgold Resources (NASDAQ:GOLD)

Jayne Crisman03 mins

Novartis AG (ADR) (NYSE:NVS) announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults…

Read More
Gilead Sciences GILD NASDAQ:GILD

Hot Alert: IAMGOLD (NYSE:IAG), Barrick Gold Corporation (USA) (NYSE:ABX), Goldcorp Inc. (USA) (NYSE:GG), Randgold Resources Ltd. (ADR) (NASDAQ:GOLD), ConocoPhillips (NYSE:COP)

Colin Pettis03 mins

Now that Toronto’s IAMGOLD Corp (USA) (NYSE:IAG) is drilling at the Monster Lake gold project 45 km southwest of Chibougamau, the property is shows signs of living up to its name. Hole ML-14-108 returned 11.55 g/t Au over 10.47 metres, including 48.90 g/t over 2.0 metres. Hole ML-14-110 assayed 13.65 g/t Au over 3.77 metres,…

Read More

Goldcorp Incurs Elevated Cash Costs in 1Q While Increasing Production

John Meady02 mins

Goldcorp GG reported disappointing first-quarter results Thursday, with considerable production growth that was met with sizable cost inflation. While the firm’s key growth projects remain on track to boost production, we believe its elevated operating expenses do not show signs of material remission. Goldcorp’s cost position rests near the middle of the industry cost curve,…

Read More